

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 8, 2004 (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/727,172
Filing Date		12/03/2003	
First Named Inventor		Amine ABINA	
Group Art Unit		1632	
Examiner Name		Unknown	
Attorney Docket Number		065691-0345	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AW		ABINA et al., "Thrombopoietin (TPO) Knockout Phenotype Induced by Cross-Reactive Antibodies Against TPO Following Injection of Mice with Recombinant Adenovirus Encoding Human TPO," The American Association of Immunologists, (1998), pp. 160, 4481-4489.	
		ABONHOUR et al., "Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells," Nature Medicine, Vol. 6, No. 6, June 2000, pp. 652-658.	
		ALEXANDER et al., "Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl," 1996 by the American Society of Hematology, Blood, Vol. 87, No. 6, (March 15, 1996), pp. 2162-2170.	
		ARMENTANO et al., "Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion," Human Gene Therapy 6:1343-1353 (October 1995).	
		ARMENTANO et al., "Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors," Journal of Virology, (March 1997), pp. 2408-2416, Vol. 71, No. 3, American Society for Microbiology	
		BERKNER et al., "Expression of Heterologous Sequences in Adenoviral Vectors; Current Topics in Microbiology and Immunology," Vol. 158, Springer-Verlag Berlin-Heidelberg (1992), pp. 39-66.	
		CARVER-MOORE et al., "Low Levels of Erythroid and Myeloid Progenitors in Thrombopoietin and Cmpl - Deficient Mice," The American Society of Hematology, Blood, Vol. 88, No. 3 (August 1, 1996), pp. 803-808.	
		ERTL et al., "Genetic Immunization," 1996, VIRAL IMMUNOLOGY, Vol. 9, pp. 1-9.	
		FANG et al., "Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX Expression, Human Gene Therapy," (August 1995), pp. 6:1039-1044	
		FISHER et al., "Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis," Virology 217, Article No. 0088 (1996), pp. 11-22.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.1177548.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/727,172	
				Filing Date	
				12/03/2003	
				First Named Inventor	
Date Submitted: April 8, 2004				Amine ABINA	
(use as many sheets as necessary)				Group Art Unit	
				1632	
				Examiner Name	
				Unknown	
Sheet	2	of	3	Attorney Docket Number	
				065691-0345	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
AW		GALLO-PENN et al., "Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs," Blood, January 1, 2001, Vol. 97, No. 1, pp. 107-113.	
		GE et al., "Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX," Blood, June 15, 2001, Vol. 97, No. 12, pp. 3733-3737.	
		GORZIGLIA et al., "Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy," Journal of Virology, Vol. 70, No. 6 (June 1996), pp. 4173-4178.	
		GOUGH et al., "Structure and Expression of the mRNA for Murine Granulocyte-Macrophage Colony Stimulating Factor", The EMBO Journal, Vol. 4 No. 3 (1985), pp. 645-653.	
		GRAHAM et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," J. Gen. Virol., Vol. 36, (1977), pp. 59-72.	
		GUO et al., "Evaluation of Promoter Strength for Hepatic Gene Expression In Vivo Following Adenovirus-mediated Gene Transfer," Gene Therapy, Vol. 3, (1996), pp. 802-810.	
		HO et al., "Site-directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction," Gene, 77, (1989), pp. 51-59.	
		HOSTOMSKY et al., "High-level Expression of Self-Processed HIV-1 Protease in Escherichia Coli Using a Synthetic Gene," Biochemical and Biophysical Research Communications, Vol. 161, No. 3, (June 30, 1989), pp. 1056-1063.	
		IMLER et al., "Novel Complementation Cell Lines Derived from Human Lung Carcinoma A549 Cells Support the Growth of E1-deleted Adenovirus Vectors," Gene Therapy, Vol. 3, (1996), pp. 75-84.	
		JOLLY, "Viral Vector Systems for Gene Therapy, Cancer Gene Therapy," Vol. 1, No. 1, (1994) pp. 51-64.	
		KAPLAN et al., "Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung," Human Gene Therapy, Vol. 8, (January 1, 1997), pp. 45-56.	
		KAY et al., "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector," Nature America, Inc., Vol. 24, March 2000, pp. 257-261.	
		KAY et al., "Long-term Hepatic Adenovirus-mediated Gene Expression in Mice Following CTLA4lg Administration," Nature Genetics, Vol. 11, (October 1995), pp. 191-197.	
		KOCHANNEK et al., "A New Adenoviral Vector: Replacement of All Viral Coding Sequences With 28 kb of DNA Independently Expressing Both Full-length Dystrophin and β -galactosidase," Proc. Natl. Acad. Sci. USA, Vol. 93, (June 1996), pp. 5731-5736.	
		LIEBER et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo," Journal of Virology, Vol. 70, No. 12, (Dec. 1996), pp. 8944-8960.	
		MAIONE et al., "An Improved Helper-Dependent Adenoviral Vector Allows Persistent Gene Expression After Intramuscular Delivery and Overcomes Preexisting Immunity to Adenovirus," PNAS, Vol. 98, No. 11, (May 22, 2001), pp. 5986-5991.	
		MARSHALL et al., "Gene therapy's growing pains," 1995, SCIENCE, Vol. 269, pp. 1050-1055.	
		MYERS et al., "A General Method for Saturation Mutagenesis of Cloned DNA Fragments," Science, Vol. 229, (July 19, 1985), pp. 242-247.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.1177548.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/727,172	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Amine ABINA			
Date Submitted: April 8, 2004		Group Art Unit		1632	
(use as many sheets as necessary)		Examiner Name		Unknown	
Sheet	3	of	3	Attorney Docket Number	
				065691-0345	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
AW		NEEDLEMAN et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," J. Mol. Biol., Vol. 48, (1970), pp. 443-453.	
		ORKIN et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy," 1995, NIH.	
		PANOUTSAKOPOULOU et al., "Analysis of the Relationship between Viral Infection and Autoimmune Disease," Immunity, Vol. 15, pp. 137-147, July 2001, Cell Press.	
		PEARSON et al., "Improved Tools for Biological Sequence Comparison," Proc. Natl. Acad. Sci. USA, Vol. 85, (April 1988) pp. 2444-2448.	
		ROSS et al., "Gene therapy in the United States: A five-year status report," 1996, HUMAN GENE THERAPY, Vol. 7, pp. 1781-1790.	
		SMITH et al., "Comparison of Biosequences, Advances in Applied Mathematics," Vol. 2, (1981), pp. 482-489.	
		STRATFORD-PERRICAUDET et al., "Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector, Human Gene Therapy," Vol. 1, (1990), pp. 241-256.	
		TIZARD, "Immunology An Introduction," Second Edition, Saunders College Publishing, (1988), pp. 264-270.	
		TRIPATHY et al., "Immune Responses to Transgene-encoded Proteins Limit the Stability of Gene Expression After Injection of Replication-Defective Adenovirus Vectors," Nature Medicine, Vol. 2, No. 5, (May 1996), pp. 545-550.	
		VERMA et al., "Gene therapy : promises, problems and prospects," 1997, NATURE, Vol. 389, pp. 239-242.	
		WENDLING et al., "c-Mpl Ligand is a Humoral Regulator of Megakaryocytopoiesis," Nature, Vol. 369, (June 16, 1994), pp. 571-574.	
		WUCHERPFENNIG et al., "Molecular Mimicry in T Cell-Mediated Autoimmunity: Viral Peptides Activate Human T Cell Clones Specific for Myelin Basic Protein," Cell Press, Vol. 80, 695-705, March 10, 1995	
		YANG et al., "Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy," Proc. Natl. Acad. Sci. USA, Vol. 91, (May 1994), pp. 4407-4411.	
		YANG et al., "Immune Responses to Viral Antigens Versus Transgene Product in the Elimination of Recombinant Adenovirus-Infected Hepatocytes In Vivo," Gene Therapy, Vol. 3, (1996), pp. 137-144.	
		YANG et al., "Inactivation of E2a in Recombinant Adenoviruses Improves the Prospect for Gene Therapy in Cystic Fibrosis," Nature Genetics, Vol. 7, (July 1994), pp. 362-369.	
		YANG et al., "MHC Class I-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant Adenoviruses," Immunity, Vol. 1, (August, 1994), pp. 433-442.	
		YANG et al., "Role of Viral Antigens in Destructive Cellular Immune Responses to Adenovirus Vector-Transduced Cells in Mouse Lungs," Journal of Virology, Vol. 70, No. 10, (October 1996), pp. 7209-7212.	
		ZI-SHAN et al., "Molecular Mimicry by Herpes Simplex Virus-Type 1: Autoimmune Disease After Viral Infection," Science, Vol. 279, February 27, 1998, pp. 1344-1347.	
		ZSENGELLER et al., "Persistence of Replication-Deficient Adenovirus-Mediated Gene Transfer in Lungs of Immune-Deficient (nu/nu) Mice," Human Gene Therapy, Vol. 6, (April 1995) pp. 457-467.	

Examiner Signature	/Anne Marie Wehbe/ (03/04/2007)	Date Considered	03/04/2007
--------------------	---------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.1177548.1


SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/727,172
 Filing Date December 3, 2003
 First Named Inventor Amine ABINA
 Examiner Name Anne Marie Sabrina Wehbe
 Attorney Docket Number 034253-002

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
AW	2003/9139221	A1	High et al.	07-10-2003

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
AW	Pia GALLE et al., "Knocking out IL-6 by Vaccination," <i>Eur. J. Immunol.</i> , 2004, Vol. 34, pp. 291-300, published by WILEY-CCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
AW	Jennifer COUZIN, "Sperm-Tracking Vaccine Blocks Male Fertility in Monkeys," <i>Science</i> , Vol. 306, November 12, 2004, page 1117, published by AAAS, Washington, D.C.
AW	M. G. O'RAND et al., "Reversible Immunocontraception in Male Monkeys Immunized with Eppin," <i>Science</i> , Vol. 306, November 12, 2004, pp. 1189-1190, published by AAAS, Washington, D.C.

Examiner Signature	/Anne Marie Wehbe/ (03/04/2007)	Date Considered	03/04/2007
--------------------	---------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.